Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of A Standardized Treatment Approach Comprising Plasma Exchange, Intravenous Immunoglobulin and Rituximab on Kidney Transplant Recipients With Acute or Chronic Antibody-Mediated Rejection

NCT04367610 is registered in ClinicalTrials.gov with Istanbul University as lead sponsor.

NCT NCT04367610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04367610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of A Standardized Treatment Approach Comprising Plasma Exchange, Intravenous Immunoglobulin and Rituximab on Kidney Transplant Recipients With Acute or Chronic Antibody-Mediated Rejection
Lead sponsor
Istanbul University
Phase
Observational
Overall status
Completed
Start date
September 1, 2019
Completion date
December 31, 2020
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection, graft loss, kidney transplant rejection